Table 2.
MfERG changes during follow-up
| Worsened | Unmodified | Improved | ||||
|---|---|---|---|---|---|---|
| n | % | n | % | n | % | |
| R1 RAD | ||||||
| AMD-P | 8 | 57.14 | 3 | 21.43 | 3 | 21.43 |
| AMD-M | 0 | 0 | 2 | 14.29 | 12 | 85.71 |
| R2 RAD | ||||||
| AMD-P | 3 | 21.43 | 6 | 42.86 | 5 | 35.71 |
| AMD-M | 2 | 14.29 | 0 | 0 | 12 | 85.71 |
| R3 RAD | ||||||
| AMD-P | 2 | 14.29 | 6 | 42.86 | 6 | 42.86 |
| AMD-M | 2 | 14.29 | 4 | 28.57 | 8 | 57.14 |
| R4 RAD | ||||||
| AMD-P | 0 | 0 | 11 | 78.57 | 3 | 21.43 |
| AMD-M | 3 | 21.43 | 4 | 28.57 | 7 | 50 |
| R5 RAD | ||||||
| AMD-P | 4 | 28.57 | 4 | 28.57 | 6 | 42.86 |
| AMD-M | 1 | 7.143 | 7 | 50 | 6 | 42.86 |
Individual changes after 6 months of follow-up of multifocal electroretinogram (mfERG) R1–R5 N1–P1 response amplitude density (RAD) values observed in AMD eyes treated with placebo (AMD-P eyes) or with Macuprev® (AMD-M eyes). R1–R5 refers to localized mfERG responses averaged in five eccentricity areas between the fovea and the mid-periphery: 0–2.5° (R1), 2.5–5° (R2), 5–10° (R3), 10–15° (R4), and 15–20° (R5). Unmodified = within the 95% confidence test–retest limit; improved = increase in values of mfERG RAD that exceeded the 95% confidence test–retest limit; worsened = reduction in values of mfERG RAD that exceeded the 95% confidence test–retest limit; n number of eyes